A5100372020- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Metal complexes synthesis and properties
- Nanoparticle-Based Drug Delivery
- Nanoplatforms for cancer theranostics
- Crystal structures of chemical compounds
- RNA Interference and Gene Delivery
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Magnetism in coordination complexes
- Protein Degradation and Inhibitors
- Synthesis and bioactivity of alkaloids
- Histone Deacetylase Inhibitors Research
- Cancer Immunotherapy and Biomarkers
- Graphene and Nanomaterials Applications
- Metal-Organic Frameworks: Synthesis and Applications
- Synthesis and Biological Evaluation
- Cancer therapeutics and mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Synthesis and biological activity
- Hematopoietic Stem Cell Transplantation
Jiangsu University
2025
Capital Medical University
2022-2025
Tianjin Fire Research Institute
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2014-2024
China Pharmaceutical University
2015-2024
University of Shanghai for Science and Technology
2024
Jilin University
2009-2024
University of Chinese Academy of Sciences
2020-2024
First Hospital of Jilin University
2009-2024
State Key Laboratory of Natural Medicine
2016-2024
To investigate the efficacy of combination FLT3 inhibitors midostaurin or gilteritinib with Bcl-2 inhibitor venetoclax in FLT3-internal tandem duplication (ITD) acute myeloid leukemia (AML) and underlying molecular mechanism.Using both FLT3-ITD cell lines primary patient samples, Annexin V-FITC/propidium iodide staining flow cytometry analysis were used to quantify death induced by gilteritinib, alone venetoclax. Western blot was performed assess changes protein expression levels members...
A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 CDK inhibition antiproliferative activities. structure-activity-relationship study illustrates the incorporation a pyrimidine-fused heterocycle at position 4 pyrazole is critical for inhibition. Compound 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, CDK6 with IC50 values in nanomolar range, shows MV4-11 cells (IC50: 0.008 μM), correlates...
O
Clear cell renal carcinoma (ccRCC) exhibits considerable heterogeneity, with approximately 25% of localized cases susceptible to relapse, highlighting the challenge absence reliable predictive biomarkers for personalized treatment. Meanwhile, metastatic is characterized by unfavorable survival rates, and although Sunitinib offers partial benefits, clinical advantages are often constrained drug resistance adverse side effects. Here, MAGI3 was associate ccRCC progression, as identified through...
Ni( ii ) and Pd( complexes of hexaphyrin(2.1.2.1.2.1) were obtained. The crystal structures 1 O 2 generation study indicated the inserted metal ions to control molecular structural physicochemical properties hexaphyrin(2.1.2.1.2.1).
Development of unique theranostic nanoplatforms for tumor imaging and therapy remains an active topic in current nanomedicine.Here, we designed a novel targeted nanoplatform enhanced T 1 -weighted magnetic resonance (MR) imaging-guided chemotherapy by constructing layered double hydroxide (LDH)-stabilized ultrasmall iron oxide (Fe 3 O 4 ) nanoparticles with hyaluronic acid (HA) modified as targeting agents, anticancer drug doxorubicin (DOX) loaded high loading efficiency.Methods: The...
Oxidative stress-induced vascular endothelial cell (VEC) injury is a major mechanism in the initiation and development of atherosclerosis. Lunasin, soybean-derived 43-aa peptide, has been previously shown to possess potent antioxidant anti-inflammatory activities other than its established anticancer activities. This study investigated effects lunasin on protecting VECs from oxidative damage inhibiting atherosclerotic plaque progression apolipoprotein E-deficient (ApoE
Background: Ulcerative colitis (UC) is a chronic inflammatory gastrointestinal disease, notoriously challenging to treat.Previous studies have found positive correlation between thymic atrophy and severity.It was, therefore, worthwhile investigate the effect of thymopentin (TP5), synthetic pentapeptide corresponding active domain thymopoietin, on colitis.Methods: Dextran sulfate sodium (DSS)-induced mice were treated with TP5 by subcutaneous injection.Body weight, colon length, immune organ...
Acute myeloid leukemia (AML) remains a difficult disease to treat and requires new therapies improve treatment outcome. Wee1 inhibitors have been used prevent activation of the G2 cell cycle checkpoint, thus enhancing antitumor activity DNA damaging agents. In this study, we investigated MK-1775 in AML lines diagnostic blast samples identify sensitive subtypes as well possible mechanisms resistance. vitro cytotoxicities blasts were measured using MTT assays. The effects on progression...
Abstract Active tumor‐targeting drug delivery has great potency in cancer therapy. However, the targeting efficiency of traditional active nanotherapeutic drugs is limited by scarcity their accessible targets/receptors tumors. Here, a novel self‐amplifying strategy with chain reaction mechanism developed. A coagulation peptide (GNQEQVSPLTLLKXC, termed A15)‐decorated poly(L‐glutamic acid)‐ graft ‐maleimide poly(ethylene glycol)/combretastatin A4 conjugate (A15‐PLG‐CA4) prepared to obtain...
Purpose: Non-small cell lung cancer (NSCLC) is an aggressive tumor with high mortality and poor prognosis. In this study, we designed a liposome encapsulating polymeric micelles (PMs) loaded vinorelbine (NVB) cis-diamminedichloroplatinum (II) (cisplatin or CDDP) for the treatment of NSCLC. Materials Methods: Sodium poly(α-l-glutamic acid)-graft-methoxy-polyethylene glycol (PLG-G-PEG 5K ) was used to prepare NVB-loaded NVB-PMs CDDP-loaded CDDP-PMs that were co-encapsulated into liposomes by...
Abstract About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor approved by the US FDA for use in adult FLT3-mutated relapsed or refractory AML patients. Monotherapy, while efficacious, shows short-lived responses, highlighting need combination therapies. Here we show that gilteritinib CUDC-907, dual PI3K histone deacetylases,...
Aplastic anaemia (AA) is defined as a pancytopenia caused by bone marrow failure, and its pathogenesis thought to involve autoimmune processes. Several predictive markers of the response immunosuppressive therapy (IST) have been proposed, which appear reflect immune pathophysiology. We prospectively investigated presence human leucocyte antigen (HLA)-DR15, minor population paroxysmal nocturnal haemoglobinuria (PNH)-type cells, antibodies recently identified autoantigen postmeiotic...